Aptamer Group plc has reported that it has won a new contract with a top-10 pharma firm.

Aptamer is a developer of synthetic binders for the life sciences industry.

The £112,000 contract ‘represents success-based repeat business with an existing partner, focusing on the development of Optimer binders against two protein targets to support the partner’s internal biomarker research’.

It builds on the group’s recent success in delivering validated Optimer binder pairs for a top-5 pharma partner. Aptamer retains ownership supporting future licensing and royalty opportunities.